Product Description

🔹 Product Overview
Gonal-F 900 IU/1.5 mL is a prescription fertility treatment injection used in assisted reproductive technologies and infertility management.
Contains Follitropin Alfa, a recombinant human follicle-stimulating hormone (r-hFSH) that helps stimulate ovarian follicle development in women and sperm production in men.
Supplied as a prefilled multidose pen for subcutaneous administration under medical supervision.

🔹 Key Uses
Treatment of female infertility due to ovulation disorders
Controlled ovarian stimulation during IVF and other assisted reproductive techniques (ART)
Management of infertility in women with inadequate follicle development
Treatment of male infertility associated with hypogonadotropic hypogonadism
Supports stimulation of sperm production when used with appropriate hormonal therapy.

🔹 Composition
Active ingredient: Follitropin Alfa 900 IU
Strength: 900 IU / 1.5 mL
Therapeutic class: Gonadotropin / Follicle-Stimulating Hormone (FSH)

🔹 How It Works
Mimics the action of natural follicle-stimulating hormone (FSH).
Stimulates growth and maturation of ovarian follicles in women.
Supports estrogen production and ovulation.
In men, helps stimulate sperm production when combined with other fertility hormones.

🔹 Key Benefits
Widely used in IVF and fertility treatment protocols
Helps promote development of mature eggs for assisted reproduction
Supports ovulation induction in eligible patients
Convenient multidose prefilled pen design
Provides precise dosing as determined by fertility specialists.

🔹 Dosage and Administration
Use only under the supervision of a fertility specialist.
Administered as a subcutaneous injection.
Dosage is individualized based on treatment response and fertility goals.
Regular ultrasound and hormone monitoring are typically required during therapy.

🔹 Possible Side Effects
Injection site pain or redness
Headache
Abdominal discomfort
Ovarian enlargement
Nausea
Ovarian Hyperstimulation Syndrome (OHSS) in susceptible patients.

🔹 Precautions
Use only after a complete fertility evaluation.
Not recommended during pregnancy.
Inform your doctor about ovarian cysts, endocrine disorders, or previous fertility treatment complications.
Close monitoring is essential to reduce the risk of excessive ovarian stimulation.